Novartis AG & Anr. v. Cipla Ltd., CS(OS) 3812/2014, Delhi High Court, decided on 9 January 2015.
Background
This case arose out of a patent dispute between Novartis AG and Cipla Ltd. Novartis held Indian Patent No. 222346 for the drug Indacaterol, including its salt form Indacaterol Maleate, which is used for treating Chronic Obstructive Pulmonary Disease (COPD). The patent had been granted in 2008 and was still in force at the time of the suit. Novartis marketed the drug in India under the brand name ONBREZ, mainly through importation and distribution arrangements. In October 2014, Cipla launched its own version of the same drug under the names UNIBREZ/INDAFLO at a significantly lower price. Novartis filed a suit before the Delhi High Court alleging patent infringement and sought an interim injunction to restrain Cipla from manufacturing and selling the product during the pendency of the trial.
Cipla resisted the injunction by arguing that:
- The patent was not being adequately “worked” in India.
- The drug was available only in very small quantities.
- The price charged by Novartis was too high.
- Public interest and the constitutional right to health required wider and cheaper access.
- The patent itself was vulnerable to revocation.
Issues for Determination
The Court mainly had to decide:
- Whether Novartis had established a prima facie case of patent infringement.
- Whether the patent was being properly “worked” in India.
- Whether public interest considerations should prevent the Court from granting an interim injunction.
- Whether the balance of convenience was in favour of Novartis or Cipla.
Key Holding of the Court
The Delhi High Court granted an interim injunction in favour of Novartis. Court held that: The patent was valid on its face and had not been revoked. Cipla’s product contained Indacaterol and therefore prima facie infringed the patent. Importing the drug into India could qualify as “working” of the patent; there is no mandatory requirement that it must be manufactured in India. Public interest arguments, although important, must be addressed within the statutory framework of the Patents Act (for example, through compulsory licensing). They cannot automatically defeat a patent holder’s rights in an infringement suit. The balance of convenience favoured the patentee, since patent rights are statutory monopolies granted for a limited period. Cipla was restrained from manufacturing and selling the drug during the pendency of the suit.
Statutory Provisions Involved
The main provisions discussed in the case were: Section 48, Patents Act, 1970 which Grants exclusive rights to the patentee to prevent others from making, selling, or importing the patented product. Section 108 which Provides relief in cases of infringement, including injunctions. Section 83 Lays down general principles regarding working of patents and public interest. Sections 84 and 92 Deal with compulsory licensing when public requirements are not met. Section 64 Provides grounds for revocation of a patent. The Court emphasized that if there are concerns regarding non-working or affordability, the proper remedy is to invoke compulsory licensing provisions rather than deny an injunction in an infringement suit.
Doctrinal Significance
In my view, this case is important for several reasons:
- Importation as Working: The Court clarified that manufacturing in India is not compulsory. Importation can amount to working of the patent.
- Public Interest within Statutory Limits: The decision shows that while public interest is relevant, it must be considered within the structure of the Patents Act. Courts should not override patent rights merely on broad constitutional grounds when specific statutory remedies exist.
- Strong Interim Protection: The judgment reinforces the principle that once a patent is granted and remains unchallenged, it enjoys a presumption of validity at the interim stage.
- Balancing Innovation and Access: The case demonstrates how Indian courts attempt to balance patent protection with access to medicines, but through legally structured mechanisms like compulsory licensing.